Back

Wobble Vaccines: Cross-Strain Protection Through Epitope Hierarchy Manipulation

McIlroy, P. R.; Zinzow-Kramer, W. M.; Ellis, M. L.; Melief, E.; Ali, M.; Peck, H. E.; Sasser, L. E.; Vanover, D.; Santangelo, P. J.; Suthar, M. S.; Voigt, E. A.; Woodruff, M. C.

2026-07-01 immunology
10.64898/2026.07.01.735277 bioRxiv
Show abstract

Vaccination remains the most successful preventative measure against viral infection, but methods to stably deter rapidly-evolving pathogens have remained elusive. Vaccines capable of incorporating and anticipating viral evolution could address current challenges in seasonal vaccination efforts against SARS-CoV-2 and influenza where economic and disease burdens remain high despite decades of combined study. Rare epitope suppression (RES) is an underutilized concept within vaccine design, where humoral epitope targeting can be molded using complex antigen pools. Based in mRNA vaccine technology, 'wobble vaccines' represent the novel application of RES to human pathogens designed to anticipate and resist viral evolution. To establish this platform, public SARS-CoV-2 sequencing data was compiled from the first two years of the COVID-19 pandemic to identify high-diversity sites across the receptor binding domain (RBD) of the spike protein. Wobble RBD (WobbRBD) libraries reflecting that entropy were synthesized and incorporated into established self-amplifying (SA) vaccine constructs. Animals immunized with these complex antigen pools showed no obvious adverse effects. By three days-post vaccination, WobbRBD stimulated robust primary immune activation with distinctive characteristics compared to traditional single-strain vaccine modalities. By day 14, germinal centers, class switching, and antibody-secreting cells were induced, creating potent SARS-CoV-2 spike-binding IgG antibodies. Despite similar overall activation profiles, WobbRBD generated significantly increased breadth against SARS-CoV-2 variant spikes in comparison to single-strain controls -- even against future-emerging strains. Taken together, wobble vaccines represent a novel method for anticipating and preventing viral escape with promising applications in SARS-CoV-2, influenza, HIV, and beyond.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Nature Communications
5641 papers in training set
Top 19%
9.5%
2
Cell
431 papers in training set
Top 0.7%
7.8%
3
npj Vaccines
67 papers in training set
Top 0.1%
7.2%
4
Frontiers in Immunology
638 papers in training set
Top 2%
6.6%
5
Science
477 papers in training set
Top 2%
4.3%
6
eLife
5828 papers in training set
Top 28%
4.3%
7
Cell Reports
1498 papers in training set
Top 10%
4.0%
8
Immunity
67 papers in training set
Top 0.5%
4.0%
9
Cell Reports Medicine
153 papers in training set
Top 0.9%
3.2%
50% of probability mass above
10
Cell Discovery
57 papers in training set
Top 0.3%
3.1%
11
iScience
1154 papers in training set
Top 9%
2.6%
12
Cancer Cell
42 papers in training set
Top 0.6%
2.4%
13
Nature
645 papers in training set
Top 5%
2.4%
14
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 22%
2.4%
15
Nature Medicine
125 papers in training set
Top 1%
2.1%
16
Science Advances
1243 papers in training set
Top 17%
2.1%
17
Molecular Therapy
81 papers in training set
Top 0.8%
2.1%
18
PLOS Pathogens
820 papers in training set
Top 6%
1.7%
19
mAbs
32 papers in training set
Top 0.3%
1.3%
20
Scientific Reports
3612 papers in training set
Top 62%
1.3%
21
mBio
833 papers in training set
Top 9%
1.1%
22
Science Immunology
88 papers in training set
Top 2%
1.1%
23
Journal of Controlled Release
44 papers in training set
Top 0.6%
1.1%
24
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 1%
1.1%
25
eBioMedicine
183 papers in training set
Top 4%
1.1%
26
Science Translational Medicine
127 papers in training set
Top 3%
1.1%
27
PLOS ONE
5266 papers in training set
Top 56%
1.1%
28
Med
39 papers in training set
Top 0.5%
1.0%
29
Nature Immunology
79 papers in training set
Top 2%
0.8%
30
EMBO Molecular Medicine
95 papers in training set
Top 3%
0.8%